Document:

Exhibit 10.1

 

Research Agreement

 

Pfizer
Inc, a Delaware
corporation with an address at 235 East 42nd Street, New York, NY 10017 and its
Affiliates (“Pfizer”), and Power3 Medical Products,
Inc. (“Power3”), a New York corporation with an address of 3400 Research
Forest Drive, The Woodlands, TX  77381,
enter into this Agreement for the conduct of studies described below.

 

1.             DEFINITIONS:  “Affiliates”
for shall mean any corporation, firm, partnership or other entity which
directly or indirectly controls, is controlled by, or is under common control
with either of the parties.

 

2.             SCOPE OF WORK:  Pfizer
would like to further evaluate the NuroPro assay capabilities. Power3 has
agreed to test blinded and unblinded samples provided by Pfizer to facilitate
the evaluation (“Study”) attached to and made part of this Agreement as Exhibit
A.  Power3, under the direction of
principal investigator Dr. Ira Goldknopf (“Principal Investigator”), will
perform the Study.

 

3.             TERM:  The term of
this Agreement is for twelve (12) months from the date of the last party to
execute this Agreement.

 

4.             INFORMATION EXCHANGE:  There shall be no funding supplied by either Party to
conduct the Proposal, provided, however, that Pfizer will provide Power3 with
the materials as described below, and Power3 will perform the work described in
the Study, and the Parties will exchange information as required to complete
their respective obligations under this Agreement.

 

5.             INTELLECTUAL
PROPERTY: Power3 will provide Pfizer with the results of the Study
in the format given in Exhibit A.  Pfizer
and Power3 will be free to use the results of the Study for their own research
purposes.  With that exception, neither
Party conveys any intellectual property to the other.

 

6.             CONFIDENTIALITY: 
Neither Party will disclose any confidential information to the other
under this Agreement.

 

7.             TRANSFER
OF MATERIALS:  In order to complete the Proposal, Pfizer
shall send to Power3 Pfizer biological samples (“Materials”), described in the
Proposal.  Pfizer will be responsible for
packaging and sending the Materials to

 

 

 

Power3 with an appropriate method, time and destination to be agreed
upon by both Parties as necessary. 
Power3 agrees:

 

i.      to use the Materials only to complete the
work in the Proposal;

 

ii.     that it will not transfer the Materials to
any third parties;

 

iii.            that the Materials will be used only in Power3
laboratories and only by laboratory personnel under Power3’s immediate and
direct control;

 

iv              that the Materials will be received, handled, stored,
used and disposed of in compliance with all applicable federal, state and local
laws, regulations and guidelines, and in accordance with safe and prudent
practices;

 

v.              that Power3 has adequate systems, procedures and
personnel to review and oversee arrangements for the receipt, handling,
storage, use and disposal of experimental materials of the nature of the
Materials and that they will ensure that all persons involved in receiving,
handling, storing, using or disposing of the Materials are adequately qualified
by training and experience to do so safely and legally.

 

8.             RIGHTS TO MATERIAL:  The furnishing of the Materials by Pfizer to Power3
shall not constitute any grant or license to Power3 under any legal rights now
or later held by Pfizer, other than as stated in this Agreement.  The furnishing of the results of the Proposal
by Power3 to Pfizer shall not constitute any grant or license to Pfizer under
any legal rights now or later held by Power3, other than as stated in this
Agreement.

 

9.             REPORTS:  A written
summary report will be submitted by Power3 to the Pfizer describing the results
of the Proposal within thirty (30) days following completion of the Proposal.

 

10.          PUBLICITY:  No press
releases or other statements, intended for use in the public or private media,
in connection with this Agreement shall be made by Pfizer or Power3 without the
prior written consent of the other Party. 
If either Party is required by law or governmental regulation to
describe its relationship to the other, it shall promptly give the other Party
notice with a copy of any disclosure it proposes to make.  This does not include internal documents
available

 

 

2

 

to the public, which
identify the existence of this agreement.

 

11.           ENTIRE
AGREEMENT:  This Agreement
sets forth the entire agreement between Pfizer and Power3 as to its subject
matter.  None of the terms of this
agreement shall be amended except in writing signed by both parties.

 

12.           BREACH:  If either party breaches this agreement, the
other may terminate it if the breaching party does not cure the breach within
thirty (30) days of written notice of the same. 
The right of termination shall be an addition to any other rights the
terminating party may have, at law or equity, pursuant to this Agreement.

 

13.           COMPLIANCE
WITH LAWS:  Both Pfizer and
Power3 shall comply in all material respects with the requirements of all
applicable laws, rules, regulations and orders of any government authority in
handling or disposing of biological reagents.

 

14.           CHOICE OF
LAW:  This Agreement shall be
construed in accordance with the laws of the State of New York.

 

	
  Agreed:

  	
   

  	
   

  	
  Agreed:

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Power3 Medical Products, Inc.

  	
   

  	
  Pfizer Inc

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Steven B.
  Rash

  	
   

  	
  By:

  	
  /s/ BJ Bormann

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Steven B. Rash

  	
   

  	
  BJ Bormann

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Chairman &
  CEO

  	
   

  	
  Vice President,
  Strategic Alliances

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  10/13/05

  	
   

  	
  Date:

  	
  10-11-2005

  	
   

  
													

 

3Exhibit
10.2

 

 

NOTE (“the
Note”)

 

Power3 Medical Products, Inc., a New York
corporation (the “Company”) for value received hereby promises to pay Ira L. Goldknopf (“Payee”) on or
before March 6, 2006, (“Maturity Date”); the principal amount of thirty nine thousand two hundred thirty one dollars ($39,231.00) (“Principal”).

 

Should the Principal not be repaid as of March
6, 2006 interest of 6 % per year on any unpaid Principal amount will be earned
by the Payee until such time as all of the Principal amount is repaid.  This Note may be repaid at any time prior to March
6, 2006 without interest or penalty.

 

In no event shall interest contracted for,
charged or received hereunder, plus any other charges in connection herewith
which constitute interest, exceed the maximum interest permitted by applicable
law. The amounts of such interest or other charges previously paid to the
holder of the Note, if any, in excess of the amounts permitted by applicable
law shall be applied by the holder of the Note to reduce the principal of the
indebtedness evidenced by the Note, or, at the option of the holder of the
Note, be refunded. To the extent permitted by applicable law, determination of
the legal maximum amount of interest shall at all times be made by amortizing,
prorating, allocating and spreading in equal parts during the period of the
full stated term of the loan and indebtedness, all interest at any time
contracted for, charged or received from the Maker hereof in connection with
the loan and indebtedness evidenced hereby, so that the actual rate of interest
on account of such indebtedness is uniform throughout the term hereof.

 

Notices, payments, requests, and other
communications to the respective parties hereunder shall be in writing, and
shall be deemed received when delivered personally, by facsimile, or first
class certified mail, return receipt requested and postage prepaid, as follows:

 

If to the lender:

 

Ira L. Goldknopf

3400 Research Forest Parkway

Woodlands, Texas 77381

 

If to the Company:

 

Power3 Medical Products, Inc.

3400 Research Forest Parkway

Woodlands, Texas 77381

 

This Note is governed by and is to be
construed in accordance with the law of the State of Texas.

 

	
  Payee

  	
   

  	
  Power3
  Medical Products, Inc.

  	
   

  	
  Date

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  /s/: Ira L. Goldknopf

  	
   

  	
  /s/ John P. Burton

  	
   

  	
  October
  17, 2005

  
	
  Ira
  L. Goldknopf

  	
   

  	
  By:
  John P. Burton

  	
   

  	
   

  
	
   

  	
   

  	
  Its:
  CFOExhibit 4.1

 

	
  

  	
  

  	
  

  

 

	
  INCORPORATED UNDER THE LAWS

  	
   

  	
  OF THE STATE OF GEORGIA

  

 

	
  COMMON STOCK

  	
   

  	
  EQUIFAX
  INC.

  	
   

  	
  COMMON STOCK

  
	
   

  	
   

  	
   

  	
   

  	
  CUSIP 294429 10
  5

  

 

THIS CERTIFICATE IS
TRANSFERABLE EITHER IN ATLANTA, GEORGIA OR IN NEW YORK, NEW YORK

 

	
  This Certifies that

  	
   

  	
  SEE REVERSE
  FOR

  CERTAIN DEFINITIONS

  
	
   

  	
  SPECIMEN

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  is the Owner of

  	
   

  	
   

  

 

FULLY PAID AND NON-ASSESSABLE SHARES WITH A PAR VALUE OF $1.25 EACH OF
THE COMMON STOCK OF

 

CERTIFICATE OF STOCK

 

Equifax
Inc., transferable on the books of the Company in person or by duly authorized
attorney, upon the surrender of this certificate properly endorsed.  The
Charter of the Company authorizes the issuance of preferred stock.  The
shares represented hereby will be subordinate to any outstanding shares of
preferred stock issued pursuant to such authority with respect to dividends and
amounts payable on liquidation.  This certificate is not valid unless
countersigned by the Transfer Agent and registered by the Registrar.

Witness
the facsimile seal of the Company and the facsimile signatures of its duly authorized
officers.

 

	
  Dated

  	
  Equifax Inc.

  

 

	
   

  	
   

  	
  EQUIFAX
  INC.

  	
   

  
	
   

  	
   

  	
  CORPORATE

  	
   

  
	
   

  	
  /s/ John T.
  Chandler

  	
  SEAL

  	
     /s/
  Thomas F. Chapman

  
	
   

  	
  SECRETARY

  	
  1913

  	
  CHAIRMAN AND
  CHIEF EXECUTIVE OFFICER

  
	
   

  	
   

  	
  GEORGIA

  	
   

  

 

	
   

  	
  COUNTERSIGNED AND REGISTERED

  	
   

  
	
   

  	
  SUNTRUST
  BANK

  	
   

  
	
   

  	
   

  	
   

  	
  TRANSFER
  AGENT

  AND REGISTRAR

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  BY

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  AUTHORIZED
  SIGNATURE

  	
   

  

 

 

This Certificate also evidences
and entitles the holder hereof to in certain Rights as set forth in a Rights
Agreement between Equifax Inc. and SunTrust Bank (formerly known as SunTrust
Bank, Atlanta) dated as of October 25, 1995 (the “Rights Agreement”), the terms
of which are hereby incorporated herein by reference and a copy of which is on
file at the principal executive offices of Equifax Inc.  Under certain circumstances as set forth in
the Rights Agreement, such Rights may be redeemed, may expire, may be amended
or may be evidenced by separate certificates and no longer be evidenced by this
Certificate.  Equifax Inc. will mail to
the holder of this Certificate a copy of the Rights Agreement without charge promptly
after receipt of a written request therefor.  Under certain circumstances set forth in the
Rights Agreement, Rights beneficially owned by an Acquiring Person or any
Affiliate or Associate of an Acquiring Person (as such terms are defined in the
Rights Agreement) may become null and void.

 

EQUIFAX
INC.

 

The Company will furnish without charge to each stockholder who so
requests, the designations, preferences and relative, participating, optional
or other special rights of each class of stock or series thereof and the
qualifications, limitations or restrictions of such preference and/or
rights.  Any such request should be
addressed to the Secretary of Equifax Inc. or to the Transfer Agent named on
the face of this certificate.

 

The following
abbreviations, when used in the inscription on the face of this certificate,
shall be construed as though they were written out in full according to
applicable laws or regulations:

 

	
  TEN COM

  	
  —

  	
  as tenants
  in common

  	
  UNIF
  GIFT MIN ACT—                  Custodian                  

  
	
  TEN ENT

  	
  —

  	
  as tenants
  by the entireties

  	
   

  	
   (Cust)

  	
       (Minor)

  
	
  JT TEN

  	
  —

  	
  as joint
  tenants with right of

  	
   

  	
  under
  Uniform Gifts to Minors

  
	
   

  	
   

  	
  survivorship
  and not as tenants in common

  	
   

  	
  Act                

  	
   

  
	
   

  	
   

  	
   

  	
  (State)

  	
   

  

 

Additional abbreviations may also be used though not in the above list.

 

 

	
  For value
  received,                   hereby
  sell, assign and transfer unto 

  
	
  PLEASE INSERT SOCIAL SECURITY OR OTHER

  	
   

  
	
  IDENTIFYING NUMBER OF ASSIGNEE

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF
  ASSIGNEE)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  

 

shares
of the capital stock represented by the within Certificate and do hereby
irrevocably constitute and appoint

	
   

  	
   Attorney to transfer the said stock on the
  books of the within

  

named
Company with full power of substitution in the premises.

 

	
  Dated

  	
   

  	
   

  

 

	
  ý

  	
   

  	
   

  
	
  NOTICE:

  	
   

  	
  THE
  SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON
  THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT
  OR ANY CHANGE WHATEVER.

  

 

	
  SIGNATURE(S)
  GUARANTEED:

  	
   

  
	
   

  	
  THE
  SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS,
  STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP
  IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]